Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 4Tumor-Agnostic 3Breast 3Thoracic 2Genitourinary 2Dermatologic 2Head & Neck 1Endocrine 1

Conditions

Breast Neoplasms 3Neoplastic Cells, Circulating 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 184Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 94Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Digoxin × Breast × Clear all
NCT03928210 2023-12-13

Digoxin Induced Dissolution of CTC Clusters

University Hospital, Basel, Switzerland

Phase EARLY_PHASE1 Completed
58 enrolled
Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT01763931 2020-01-31

DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
6 enrolled 8 charts
Breast

Breast Neoplasms

NCT00650910 2017-11-17

Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer

GlaxoSmithKline

Phase 1 Completed
17 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡